Business Wire

Workiva and Persefoni Partner to Streamline Investor-Grade Carbon Disclosure Data

16.2.2022 15:00:00 CET | Business Wire | Press Release

Share

Workiva Inc. (NYSE:WK), the world’s leading platform for regulatory, financial and ESG reporting, and Persefoni, Inc., the leading Climate Management and Accounting SaaS Platform helping enterprises and financial institutions easily calculate, analyze, manage, and report their real-time carbon footprint, today announced a strategic partnership to provide transparent, investor-grade carbon disclosures seamlessly to joint customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220216005287/en/

The SEC and other global regulators are announcing new climate-related disclosure guidelines that will impact organizations in a pervasive way. CFOs, sustainability leaders, and their boards will need to collaborate to incorporate carbon reporting requirements of a revised regulatory framework into daily respective operations.

The partnership establishes the only reporting solution in the market that unifies transparent and connected financial and environmental, social and governance (ESG) reporting with deeper granularity around greenhouse gas accounting in accordance with the greenhouse gas protocols (GHGP) to track carbon emissions in Scope 1, indirect emissions in Scope 2, and upstream and downstream emissions in Scope 3.

“Workiva continues to develop and deliver innovative capabilities that ensure our end-to-end platform enables our customers to meet evolving ESG disclosure requirements,” said Julie Iskow, chief operating officer of Workiva. “By partnering with Persefoni, we're able to deliver investor and board-grade carbon data that can be used to make better decisions for businesses and the environment.”

A technology-enabled solution is critical to an organization becoming compliant and thereafter maintaining compliance with regulation. Workiva and Persefoni will jointly offer a connected reporting solution to seamlessly transfer carbon data between the two platforms, empowering users to pivot away from disparate spreadsheets and manual processes. This will allow users to save time, increase efficiency, and reduce complexity and risk. It will also improve overall accuracy and transparency in the record-to-report process.

“We’re excited about the value our partnership will create for our joint customers by easing the path to satisfying complex climate-related disclosure requirements,” said Kentaro Kawamori, chief executive officer of Persefoni. “Together, Workiva and Persefoni become the market leader at simplifying complex ESG and Financial filings, both today and into the future.”

The Technology Behind the Partnership:

Persefoni radically simplifies the technical barrier to entry for carbon accounting, having successfully codified the 750+ pages of the GHGP technical guidance into its platform. Additionally, Persefoni is the first and only vendor to codify the global standard for financed emissions calculations, the Partnership for Carbon Accounting Financials. The platform enables users to turn financial, operational, and supply chain data into certified carbon footprint data, greatly reducing complexity and significantly increasing time to insights across multiple climate disclosure and sustainability reporting frameworks.

The Workiva and Persefoni partnership will enable users to seamlessly integrate and transfer data between the companies’ platforms, as well as allow access to carbon benchmarking and a carbon offsets marketplace. These include: activity data, carbon footprint calculations, climate trajectory models, secondary data sets, operational, financial and supply-chain data, and more.

Joint customers will then be able to use the Workiva Framework Explorer to compare data to requirements listed across multiple frameworks, including the United Nations Sustainable Development Goals (UNSDGs), Task Force on Climate-Related Financial Disclosures (TCFD), Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Carbon Disclosure Project (CDP), and report outcomes to all stakeholders.

About Workiva

Workiva Inc. (NYSE: WK) simplifies complex work for thousands of organizations worldwide. Customers trust Workiva’s open, intelligent and intuitive platform to connect data, documents and teams. The results: more efficiency, greater transparency and less risk. Learn more at workiva.com.

Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva
Follow Workiva on Instagram: www.instagram.com/workiva

About Persefoni

Persefoni, Inc., is the leading Climate Management & Accounting Platform (CMAP). The company's Software-as-a-Service solutions enable enterprises and financial institutions to meet stakeholder and regulatory climate disclosure requirements with the highest degree of trust, transparency, and ease. As the ERP of Carbon, the Persefoni platform provides users a single source of carbon truth across their organization, enabling them to manage their carbon transactions and inventory with the same rigor and confidence as their financial transactions. Learn more at https://persefoni.com.

Follow Persefoni on LinkedIn: https://www.linkedin.com/company/persefoni.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Kevin McCarthy
Workiva Inc.
(515) 663-4471
press@workiva.com

Media Inquiries:
Susan Koehler
Persefoni, Inc.
press@persefoni.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye